ANTI-HB-EGF MONOCLONAL ANTIBODY KHK2866
Fallopian Tube Neoplasm
Kyowa Kirin Co., Ltd.monoclonal_antibodyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Fallopian Tube Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Eli Lilly and Company | Phase 3 | BB |
Inno-206 Eli Lilly and Company | Phase 3 | BB |
Trabectedin Janssen Research & Development, LLC | Phase 3 | B |
Sofetabart Mipitecan Eli Lilly and Company | Phase 3 | B |
Mirvetuximab Soravtansine Eli Lilly and Company | Phase 3 | B |
View all 39 →
Same molecule, other indications
ANTI-HB-EGF MONOCLONAL ANTIBODY KHK2866 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →